CYP19A1 and breast carcinoma: For example, many breast cancer patients received both estrogen receptor (ER) antagonist and aromatase inhibitor therapy, and many patients received more than one genotoxic therapy (e.g., anthracyclines, DNA alkylating agent, DNA synthesis inhibitor).